Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7576
+0.0075 (1.00%)
At close: Nov 28, 2025, 1:00 PM EST
0.7624
+0.0048 (0.63%)
After-hours: Nov 28, 2025, 4:29 PM EST
Xilio Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Xilio Therapeutics stock has a target of 2.00, which predicts a 163.99% increase from the current stock price of 0.76.
Price Target: $2.00 (+163.99%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 6, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Xilio Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $2 | Buy | Initiates | $2 | +163.99% | Aug 6, 2025 |
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +427.98% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +823.97% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +823.97% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +1,219.96% | Jan 27, 2023 |
Financial Forecast
Revenue This Year
39.31M
from 6.34M
Increased by 519.70%
Revenue Next Year
56.84M
from 39.31M
Increased by 44.57%
EPS This Year
-0.45
from -1.09
EPS Next Year
-0.32
from -0.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 47.9M | 85.8M | ||||
| Avg | 39.3M | 56.8M | ||||
| Low | 31.6M | 30.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 655.6% | 118.3% | ||||
| Avg | 519.7% | 44.6% | ||||
| Low | 397.4% | -23.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.46 | -0.19 | |
| Avg | -0.45 | -0.32 | |
| Low | -0.45 | -0.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.